<SEC-DOCUMENT>0001209191-23-007355.txt : 20230206
<SEC-HEADER>0001209191-23-007355.hdr.sgml : 20230206
<ACCEPTANCE-DATETIME>20230206182801
ACCESSION NUMBER:		0001209191-23-007355
CONFORMED SUBMISSION TYPE:	4/A
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20220611
FILED AS OF DATE:		20230206
DATE AS OF CHANGE:		20230206

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Duraibabu Prathyusha
		CENTRAL INDEX KEY:			0001779092

	FILING VALUES:
		FORM TYPE:		4/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		23592018

	MAIL ADDRESS:	
		STREET 1:		C/O SANGAMO THERAPEUTICS, INC.
		STREET 2:		501 CANAL BLVD.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO THERAPEUTICS, INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		7000 MARINA BLVD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		7000 MARINA BLVD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANGAMO BIOSCIENCES INC
		DATE OF NAME CHANGE:	20000208
</SEC-HEADER>
<DOCUMENT>
<TYPE>4/A
<SEQUENCE>1
<FILENAME>doc4a.xml
<DESCRIPTION>FORM 4/A SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4/A</documentType>

    <periodOfReport>2022-06-11</periodOfReport>

    <dateOfOriginalSubmission>2022-06-14</dateOfOriginalSubmission>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001001233</issuerCik>
        <issuerName>SANGAMO THERAPEUTICS, INC</issuerName>
        <issuerTradingSymbol>SGMO</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001779092</rptOwnerCik>
            <rptOwnerName>Duraibabu Prathyusha</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O SANGAMO THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>7000 MARINA BLVD.</rptOwnerStreet2>
            <rptOwnerCity>BRISBANE</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94005</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>SVP, Chief Financial Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2022-06-11</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>F</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>864</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>3.76</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>86595</value>
                    <footnoteId id="F2"/>
                    <footnoteId id="F3"/>
                    <footnoteId id="F4"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Represents shares underlying the portion of a restricted stock unit (&quot;RSU&quot;) grant that vested on June 11, 2022 which were surrendered by the Reporting Person to the Issuer solely for mandatory tax withholding purposes using the Issuer's closing stock price on June 10, 2022 of $3.76/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the &quot;2018 EIP&quot;).  This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.</footnote>
        <footnote id="F2">Includes: (a) 1,658 shares resulting from the June 11, 2022 annual vesting installment of the Reporting Person's June 11, 2021 RSU grant and 5,000 shares subject to such grant that will vest in two remaining annual installments of 2,500 shares on each of June 11, 2023 and 2024, (b) 5,501 shares subject to the Reporting Person's February 25, 2020 RSU grant that will vest in one final annual installment on February 25, 2023, (c) 9,167 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in two remaining annual installments of 4,583 shares and 4,584 shares on February 25, 2023 and 2024, respectively, (continued in footnote 3)</footnote>
        <footnote id="F3">(d) 41,000 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, and (e) 1,000 shares subject to the Reporting Person's March 25, 2020 RSU grant that will vest in one final annual installment on March 25, 2023. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.</footnote>
        <footnote id="F4">Includes 687 shares acquired on May 31, 2022 under the Issuer's 2020 Employee Stock Purchase Plan.</footnote>
    </footnotes>

    <remarks>This Form 4/A is being filed solely to correct the number of shares reported as disposed of by the Reporting Person in Item 4 of Table I, which was erroneously reported to be 842 shares.</remarks>

    <ownerSignature>
        <signatureName>Prathyusha Duraibabu, by /s/ Ron A. Metzger, Attorney-in-Fact</signatureName>
        <signatureDate>2023-02-06</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
